85 related articles for article (PubMed ID: 12071536)
1. Sheep form of leucocyte function antigen-3 (T11TS) exerts immunostimulatory and anti-tumor activity against experimental brain tumor. A new approach to biological response modifier therapy.
Sarkar S; Begum Z; Dutta S; Dutta SK; Chaudhuri S; Chaudhuri S
J Exp Clin Cancer Res; 2002 Mar; 21(1):95-106. PubMed ID: 12071536
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic effects of T11TS/S-LFA3 against nitrosocompound mediated neural genotoxicity.
Mukherjee J; Sarkar S; Ghosh A; Duttagupta AK; Chaudhuri S; Chaudhuri S
Toxicol Lett; 2004 May; 150(3):239-57. PubMed ID: 15110076
[TBL] [Abstract][Full Text] [Related]
3. The "erythrocyte receptor" of T-lymphocytes and T11 target structure (T11TS): complementary cell interaction molecules involved in T-cell activation.
Hünig T; Tiefenthaler G; Mitnacht R; Köhler C; Lottspeich F; Meuer S
Behring Inst Mitt; 1987 Jun; (81):31-40. PubMed ID: 2888455
[TBL] [Abstract][Full Text] [Related]
4. Rosetting of human T lymphocytes with sheep and human erythrocytes. Comparison of human and sheep ligand binding using purified E receptor.
Selvaraj P; Dustin ML; Mitnacht R; Hünig T; Springer TA; Plunkett ML
J Immunol; 1987 Oct; 139(8):2690-5. PubMed ID: 3309056
[TBL] [Abstract][Full Text] [Related]
5. Brain tumor inhibition in experimental model by restorative immunotherapy with a corpuscular antigen.
Gangopaddhyay SK; Sarkar S; Begum Z; Chaudhuri S; Chaudhuri S
Indian J Exp Biol; 2003 Aug; 41(8):805-13. PubMed ID: 15248476
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with T11TS / S-LFA-3 specifically induces apoptosis of brain tumor cells by augmenting intracranial immune status.
Mukherjee J; Ghosh A; Sarkar P; Mazumdar M; Banerjee C; Chaudhuri S
Anticancer Res; 2005; 25(4):2905-19. PubMed ID: 16080544
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of T11 target structure and its deglycosylated derivative nullifies the importance of glycan moieties in immunotherapeutic efficacy.
Chatterjee S; Acharya S; Kumar P; Chatterjee A; Chaudhuri S; Ghosh A; Chaudhuri S
Acta Biochim Biophys Sin (Shanghai); 2012 Mar; 44(3):259-68. PubMed ID: 22257732
[TBL] [Abstract][Full Text] [Related]
8. Serologic cross-reactivity of T11 target structure and lymphocyte function-associated antigen 3. Evidence for structural homology of the sheep and human ligands of CD2.
Tiefenthaler G; Dustin ML; Springer TA; Hünig T
J Immunol; 1987 Oct; 139(8):2696-701. PubMed ID: 2443569
[TBL] [Abstract][Full Text] [Related]
9. T11TS, the cell surface molecule binding to the "erythrocyte receptor" of T lymphocytes: cellular distribution, purification to homogeneity and biochemical properties.
Hünig T; Mitnacht R; Tiefenthaler G; Köhler C; Miyasaka M
Eur J Immunol; 1986 Dec; 16(12):1615-21. PubMed ID: 2880724
[TBL] [Abstract][Full Text] [Related]
10. T11TS/S-LFA3 induces apoptosis of the brain tumor cells: a new approach to characterise the apoptosis associated genetic changes by arbitrarily primed-PCR.
Mukherjee J; Ghosh A; Sarkar S; Mazumdar M; Sarkar P; Duttagupta AK; Chaudhuri S
Cancer Lett; 2005 May; 222(1):23-38. PubMed ID: 15837538
[TBL] [Abstract][Full Text] [Related]
11. T11 target structure exerts effector function by activating immune cells in CNS against glioma where cytokine modulation provide favorable microenvironment.
Ghosh A; Bhattacharya M; Sarkar P; Acharya S; Chaudhuri S
Indian J Exp Biol; 2010 Sep; 48(9):879-88. PubMed ID: 21506495
[TBL] [Abstract][Full Text] [Related]
12. CD2-SLFA3/T11TS interaction facilitates immune activation and glioma regression by apoptosis.
Sarkar S; Ghosh A; Mukherjee J; Chaudhuri S; Chaudhuri S
Cancer Biol Ther; 2004 Nov; 3(11):1121-8. PubMed ID: 15467439
[TBL] [Abstract][Full Text] [Related]
13. Sheep erythrocyte demonstrated better effect than IL-2 and IFN-gamma as biological response modifier against glioma in experimental model.
Sarkar S; Ghosh A; Dutta S; Roy RU; Begum Z; Mukherjee J; Chaudhuri S; Chaudhuri S
Indian J Exp Biol; 2005 May; 43(5):414-9. PubMed ID: 15900905
[TBL] [Abstract][Full Text] [Related]
14. Documentation of immune profile of microglia through cell surface marker study in glioma model primed by a novel cell surface glycopeptide T11TS/SLFA-3.
Begum Z; Ghosh A; Sarkar S; Mukherjee J; Mazumdar M; Sarkar P; Chaudhuri S
Glycoconj J; 2004; 20(9):515-23. PubMed ID: 15454689
[TBL] [Abstract][Full Text] [Related]
15. The cell surface molecule recognized by the erythrocyte receptor of T lymphocytes. Identification and partial characterization using a monoclonal antibody.
Hünig T
J Exp Med; 1985 Sep; 162(3):890-901. PubMed ID: 2411842
[TBL] [Abstract][Full Text] [Related]
16. A multimeric form of soluble recombinant sheep LFA-3 (CD58) inhibits human T-cell proliferation.
Yamashita K; Parish CR; Warren HS; Harrison LC
Immunology; 1997 Sep; 92(1):39-44. PubMed ID: 9370922
[TBL] [Abstract][Full Text] [Related]
17. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
18. Cross-linking a mAb to NKR-P2/NKG2D on dendritic cells induces their activation and maturation leading to enhanced anti-tumor immune response.
Srivastava RM; Varalakshmi Ch; Khar A
Int Immunol; 2007 May; 19(5):591-607. PubMed ID: 17369187
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of autologous rosette formation by monoclonal antibody to the sheep erythrocyte receptor.
Scheffel JW; Swartz SJ
J Immunol; 1982 Apr; 128(4):1930-2. PubMed ID: 7061854
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Changes in Immunoreactivity and Cellular Architecture during the Progressive Development of Intracranial Neoplasms and an Immunotherapeutic Schedule with a Novel Biological Response Modifier, the T11TS / S-LFA3.
Mukherjee J; Dutta S; Sarkar S; Begum Z; Ghosh A; Chaudhuri S; Chaudhuri S
Asian Pac J Cancer Prev; 2002; 3(4):325-337. PubMed ID: 12716291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
